Obesity-drug startup Obecure, which is part of the Biolight group has received FDA approval for starting Phase 2 clinical trials of OBE 101, its drug for weight control on human beings.
Obecure is already in contact with 20 medical centers in the U.S. to run the trials and to begin giving patients its drug. The first trials are expected to start the coming January to avoid the Christmas holidays, a period in which people tend to put on weight.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>